Jan 12, 2021 8:30 am EST Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
Nov 19, 2020 8:00 am EST Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Oct 9, 2020 8:30 am EDT Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
Sep 10, 2020 8:00 am EDT Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
Jul 27, 2020 8:00 am EDT Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
Jun 15, 2020 8:30 am EDT Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
Jun 10, 2020 8:30 am EDT Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
